Skip to main content

Biogen BYOOVIZ revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

BYOOVIZ revenue at Biogen came to $200,000 for the quarter to 30 Sep 2026, down 97.1% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$9.2MDec 2023$5.6MMar 2024$13.7MJun 2024$8.0MSep 2024$9.3MDec 2024$8.9MMar 2025$8.6MJun 2025$7.0MSep 2025$7.9MDec 2025$0Mar 2026$100,000Jun 2026$200,000Sep 2026
Biogen BYOOVIZ revenue, every reported period
Period endingBYOOVIZ revenueChange on a yearFiled
30 Sep 2026$200,000down 97.1%28 Oct 2026
30 Jun 2026$100,000down 98.8%29 Jul 2026
31 Mar 2026$0down 100.0%29 Apr 2026
31 Dec 2025$7.9Mdown 15.1%6 Feb 2026
30 Sep 2025$7.0Mdown 12.5%30 Oct 2025
30 Jun 2025$8.6Mdown 37.2%31 Jul 2025
31 Mar 2025$8.9Mup 58.9%1 May 2025
31 Dec 2024$9.3Mup 1.1%12 Feb 2025
30 Sep 2024$8.0Mup 15.9%30 Oct 2024
30 Jun 2024$13.7Mup 95.7%1 Aug 2024
31 Mar 2024$5.6Mdown 34.9%24 Apr 2024
31 Dec 2023$9.2M—14 Feb 2024
30 Sep 2023$6.9Mup 885.7%8 Nov 2023
30 Jun 2023$7.0Mup 1300.0%25 Jul 2023
31 Mar 2023$8.6M—25 Apr 2023
30 Sep 2022$700,000—25 Oct 2022
30 Jun 2022$500,000—20 Jul 2022
31 Mar 2022$0—3 May 2022
30 Sep 2021$0—20 Oct 2021
30 Jun 2021$0—22 Jul 2021
31 Mar 2019$0down 100.0%24 Apr 2019
30 Sep 2018$0down 100.0%23 Oct 2018
30 Jun 2018$0down 100.0%24 Jul 2018
31 Mar 2018$1.4M—24 Apr 2018
30 Sep 2017$14.2M—24 Oct 2017
30 Jun 2017$16.1M—25 Jul 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.